Where it is unclear how well a case is doing then the company should be asked about its strategy for the case to help with one’s judgment. Many biotech cases have inventive step issues. These are expected and there are normally arguments that can be formulated for responding to the Examiner’s objections. However if the case has novelty objections which are not being overcome then that may be a sign of problems that cannot be solved.
You may also wish to see related articles Top 10 Tips on Building a Patent Portfolio and What Do You Need to Know About Commercial Biotech?